Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
On January 19th, Verve Therapeutics announced it raised $94 million in investments as part of a Series B financing. The money will be used to advance the company’s gene-editing therapies, …
Read More